Chevy Chase Trust
ALXN

Chevy Chase Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Chevy Chase Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-140,836
Closed -$25.9M – 686
2021
Q2 		$25.9M Sell
140,836
-6,770
-5% -$1.16M 0.09% 209
2021
Q1 		$22.6M Sell
147,606
-9,930
-6% -$1.54M 0.08% 237
2020
Q4 		$24.6M Sell
157,536
-4,983
-3% -$640K 0.09% 214
2020
Q3 		$18.6M Sell
162,519
-15,349
-9% -$1.66M 0.07% 250
2020
Q2 		$20M Sell
177,868
-10,412
-6% -$1.11M 0.08% 233
2020
Q1 		$16.9M Buy
188,280
+3,240
+2% +$318K 0.08% 240
2019
Q4 		$20M Sell
185,040
-2,483
-1% -$266K 0.08% 262
2019
Q3 		$18.4M Buy
187,523
+69
+0% +$7.78K 0.08% 270
2019
Q2 		$24.6M Buy
187,454
+831
+0.4% +$107K 0.1% 207
2019
Q1 		$25.4M Buy
186,623
+2,796
+2% +$348K 0.11% 205
2018
Q4 		$17.9M Buy
183,827
+624
+0.3% +$73.8K 0.09% 234
2018
Q3 		$25.5M Sell
183,203
-4,223
-2% -$530K 0.11% 207
2018
Q2 		$23.3M Sell
187,426
-181
-0.1% -$21.2K 0.1% 218
2018
Q1 		$20.9M Sell
187,607
-6,168
-3% -$737K 0.09% 233
2017
Q4 		$23.2M Sell
193,775
-1,118
-0.6% -$136K 0.1% 225
2017
Q3 		$27.3M Buy
194,893
+1,197
+0.6% +$163K 0.12% 196
2017
Q2 		$23.6M Sell
193,696
-744
-0.4% -$86.6K 0.11% 213
2017
Q1 		$23.6M Buy
194,440
+5,619
+3% +$724K 0.12% 209
2016
Q4 		$23.1M Sell
188,821
-19,970
-10% -$2.44M 0.12% 195
2016
Q3 		$25.6M Sell
208,791
-4,561
-2% -$587K 0.14% 174
2016
Q2 		$24.9M Buy
213,352
+5,463
+3% +$775K 0.14% 170
2016
Q1 		$28.9M Buy
207,889
+21,324
+11% +$3.13M 0.17% 143
2015
Q4 		$35.6M Buy
186,565
+435
+0.2% +$76K 0.21% 117
2015
Q3 		$29.1M Buy
186,130
+8,280
+5% +$1.51M 0.18% 135
2015
Q2 		$32.1M Buy
177,850
+19,178
+12% +$3.31M 0.19% 133
2015
Q1 		$27.5M Buy
158,672
+8,300
+6% +$1.5M 0.17% 151
2014
Q4 		$27.8M Sell
150,372
-879
-0.6% -$163K 0.17% 145
2014
Q3 		$25.1M Buy
151,251
+9,221
+6% +$1.51M 0.16% 157
2014
Q2 		$22.2M Sell
142,030
-2,931
-2% -$463K 0.15% 166
2014
Q1 		$22.1M Buy
144,961
+1,378
+1% +$219K 0.16% 164
2013
Q4 		$19.1M Buy
143,583
+2,272
+2% +$273K 0.14% 175
2013
Q3 		$16.4M Buy
141,311
+3,604
+3% +$395K 0.13% 183
2013
Q2 		$12.7M Buy
+137,707
New +$13.3M 0.11% 211

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Chevy Chase Trust's ALXN Position: Q3 2021 in Review

Chevy Chase Trust sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 140,836 shares — an estimated $25.9M sold.

Chevy Chase Trust first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $35.6M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Chevy Chase Trust reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Chevy Chase Trust sold 140,836 Alexion Pharmaceuticals shares in Q3 2021, an estimated $25.9M.
  • Chevy Chase Trust first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Chevy Chase Trust's Alexion Pharmaceuticals position peaked at $35.6M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Chevy Chase Trust's 13F filing for Q3 2021, filed 20 Oct 2021.